Physician profile
David Dillon
NPI 1033503172
$8,603.75
in general payments reported to CMS, 2019-2025
28 companies · $2,821 in 2025
The $2,821 reported for 2025 was more than what 76% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $127 · 2021: $1,279 · 2022: $1,033 · 2023: $1,150 · 2024: $2,193 · 2025: $2,821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,907 · Education: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,907.22 |
| Education | $256.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,690.51 | 2020-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $1,410.54 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Amgen INC. | $1,076.86 | 2021-2025 | Evenity, Prolia, Prolia |
| Ucb, INC. | $651.53 | 2021-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $514.79 | 2020-2025 | Benlysta, Nucala |
| E.R. Squibb & Sons, L.L.C. | $499.90 | 2020-2025 | Orencia |
| Novartis Pharmaceuticals Corporation | $429.15 | 2021-2025 | |
| Radius Health, INC. | $382.56 | 2021-2025 | Tymlos |
| Mallinckrodt Hospital Products INC. | $245.45 | 2020-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.10 | 2022-2025 | Ofev, Cyltezo, Jardiance |
| Pfizer INC. | $181.14 | 2021-2025 | |
| Lilly USA, LLC | $150.84 | 2021-2024 | Taltz |
| Astrazeneca Pharmaceuticals Lp | $143.46 | 2021-2025 | Saphnelo |
| Horizon Therapeutics Plc | $142.77 | 2022-2023 | Krystexxa |
| Genentech USA, INC. | $135.51 | 2021-2024 | Actemra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $107.20 | 2021-2025 | Lupkynis |
| Alvogen INC | $102.01 | 2022-2025 | Teriparatide |
| Kiniksa Pharmaceuticals International, Plc | $85.76 | 2024 | Arcalyst |
| Fresenius Kabi USA, LLC | $79.03 | 2023-2025 | Idacio |
| Actelion Pharmaceuticals US, INC. | $68.14 | 2022-2024 | Opsumit |
| Sobi, INC | $59.18 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $55.32 | 2023-2025 | Purified Cortrophin Gel, Sovuna |
| Genzyme Corporation | $54.42 | 2024-2025 | |
| Organon LLC | $41.15 | 2023-2025 | Hadlima |
| Sanofi-Aventis U.S. LLC | $23.71 | 2020 | |
| Kiniksa Pharmaceuticals, Ltd. | $20.84 | 2022 | |
| Almatica Pharma LLC | $20.78 | 2022 | |
| Tonix Medicines, INC. | $16.10 | 2025 | Tonmya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.